3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
87
Breast Neoplasms
49
Prostatic Neoplasms
42
Squamous Cell Carcinoma of Head and Neck
34
Lung Neoplasms
24
Neoplasms
19
Stomach Neoplasms
18
Head and Neck Neoplasms
17
Neoplasm Metastasis
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Urinary Bladder Neoplasms
13
Carcinoma, Transitional Cell
11
Triple Negative Breast Neoplasms
10
Ovarian Neoplasms
8
Endometrial Neoplasms
8
Carcinoma, Squamous Cell
8
Adenocarcinoma
8
HER2-positive Breast Cancer
7
Non-Muscle Invasive Bladder Neoplasms
6
Melanoma
6
Carcinoma
6
Small Cell Lung Carcinoma
5
Prostatic Neoplasms, Castration-Resistant
5
Nasopharyngeal Carcinoma
5
Esophageal Neoplasms
5
Uterine Cervical Neoplasms
4
Sarcoma
4
Oropharyngeal Neoplasms
4
Fallopian Tube Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Interventions
fludarabine
4
Cyclophosphamide
4
Cisplatin
4
pembrolizumab
3
atezolizumab
3
Pemetrexed
3
fludarabine phosphate
2
entrectinib
2
durvalumab
2
cobimetinib
2
capmatinib
2
alectinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Paclitaxel
2
Nivolumab
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
spartalizumab
1
ruxolitinib
1
repotrectinib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Docetaxel
×
1 year
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled